Abstract
Polycythemia vera, essential thrombocythemia and primary myelofibrosis constitute the BCR-ABL1-negative myeloproliferative neoplasms. In this communication, I will provide an overview on their histopathology, cytogenetic findings and associated mutations, as well as summarize recent advances that have changed our approach to their diagnosis and treatment. Also included in the current review are (i) indications for ordering JAK2 or MPL mutation analysis and result interpretation, (ii) new international prognostic scoring systems, and (iii) risk-adapted therapy including the therapeutic role of immunomodulatory drugs and JAK inhibitors.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1481-1489 |
| Number of pages | 9 |
| Journal | Leukemia Research |
| Volume | 36 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 2012 |
Keywords
- Myelodysplastic syndromes (MDS)
- Myeloproliferative neoplasms (MPN)
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research